Comparative Pharmacology
Head-to-head clinical analysis: ADENOSCAN versus DRONEDARONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADENOSCAN versus DRONEDARONE.
ADENOSCAN vs DRONEDARONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adenosine is a purine nucleoside that acts as a coronary vasodilator by activating A2A adenosine receptors on vascular smooth muscle, causing hyperemia. It also slows atrioventricular (AV) nodal conduction via A1 receptor activation.
Dronedarone is a multichannel blocker that inhibits potassium (IKr, IKs, IKur), sodium (INa), and calcium (ICaL) currents, and exhibits antiadrenergic effects via noncompetitive antagonism of beta-1 and beta-2 receptors. It also prolongs atrial refractoriness and slows atrioventricular conduction.
Intravenous administration at 140 mcg/kg/min for 6 minutes (total dose 0.84 mg/kg).
400 mg orally twice daily after meals
None Documented
None Documented
Clinical Note
moderateDronedarone + Levofloxacin
"Dronedarone may increase the QTc-prolonging activities of Levofloxacin."
Clinical Note
moderateDronedarone + Norfloxacin
"Dronedarone may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderateDronedarone + Gemifloxacin
"Dronedarone may increase the QTc-prolonging activities of Gemifloxacin."
Clinical Note
moderateDronedarone + Ibandronate
"Dronedarone may increase the QTc-prolonging activities of Ibandronate."
< 10 seconds (biphasic: distribution half-life < 1 second, terminal elimination half-life ~0.6-1.5 seconds). Clinically, effects are rapidly terminated due to cellular uptake and metabolism.
Terminal half-life is 13–19 hours; steady state achieved within 4–8 days.
Primarily renal excretion of metabolites; <3% excreted unchanged in urine. Adenosine is rapidly metabolized intracellularly to inosine and adenosine monophosphate, with further degradation to uric acid. <2% eliminated in feces.
Primarily fecal (≥84%) via biliary excretion; renal excretion accounts for <6% as unchanged drug.
Category C
Category C
Antiarrhythmic
Antiarrhythmic